Preterm neonates younger than 37 weeks gestational age receiving caffeine therapy for apnea of prematurity in a NICU setting.
Preterm neonates with gestational age <37 weeks
Receiving caffeine therapy for apnea of prematurity
Hemodynamically stable before caffeine initiation
Presence of major congenital anomalies
Use of vasopressors at baseline
Severe intraventricular hemorrhage (Grade III-IV)
Preterm neonates receiving standard caffeine citrate therapy for apnea of prematurity, including a loading dose of 20-25 mg/kg followed by maintenance dosing (5-10 mg/kg daily). Cardiovascular parameters and side effects are monitored longitudinally.
Cohort
Prospective
Not listed
Change in mean arterial blood pressure after caffeine therapy in preterm neonates.
Mean change in mean arterial blood pressure (mmHg) in preterm neonates receiving caffeine therapy for apnea of prematurity, comparing post-caffeine values with baseline pre-caffeine values.
Change in perfusion index after caffeine therapy in preterm neonates.
Mean change in perfusion index (unitless value from pulse oximeter) in preterm neonates receiving caffeine therapy for apnea of prematurity, comparing post-caffeine values with baseline pre-caffeine values.
Change in heart rate after caffeine therapy in preterm neonates.
Mean change in heart rate (beats per minute) in preterm neonates receiving caffeine therapy for apnea of prematurity, comparing post-caffeine values with baseline pre-caffeine values, and documenting episodes of tachycardia defined as heart rate greater than 180 beats per minute.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
